inhaled

TD139 is a small molecule inhibitor of inhaled galectin-3 (Gal-3) with potential anti-fibrotic activity, commonly used in the study of idiopathic pulmonary fibrosis.

Sulukast is a potent inhaled leukotriene antagonist, which was found to be effective in preventing both leukotriene_x0002_and antigen-induced bronchospasm in guinea-pigs.

Budesonide (Pulmicort), an anti-inflammatory corticosteroid, has shown the effective glucocorticoid activitie and few mineralocorticoid activities. According to reports, Budesonide has extensively inhibitory effects against multiple cells types and mediators referred to allergic and nonallergic-mediated inflammatory. What's more, the anti-inflammatory action of budesonide has been revealed to contribute to the effectiveness of asthma.

Potassium iodide is used as the treatment of overactive thyroid and as protection of the thyroid gland from the influences of radiation from swallowed or inhaled radioactive iodine. It may be used after accidental exposure to radioactive iodine or before and after administration of medicine containing radioactive iodine.

GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).

Olodaterol hydrochloride (BI-1744 HCl) is a novel, long-acting β2-adrenergic agonist (EC50s: 97.7 nM for the human β2-adrenoceptor) that exerts its pharmacological effect by binding and activating β2-adrenergic receptors.

Laninamivir octanoate (CS-8958) is a long acting influenza neuraminidase (NA) inhibitor which shows superior anti-influenza virus activity.

AZD-8871 can present a novel treatment approach to chronic obstructive pulmonary disease [COPD] and potentially also asthma (in combination with an inhaled corticosteroid [ICS]).

Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs.

Cromoglicic acid , cromolyn (USAN), cromoglycate (former BAN), or cromoglicate, is traditionally described as a mast cell stabilizer, and is commonly marketed as the sodium salt sodium cromoglicate or cromolyn sodium. This drug prevents the release of inflammatory chemicals such as histamine from mast cells. Because of their convenience (and perceived safety), leukotriene receptor antagonists have largely replaced it as the non-corticosteroid treatment of choice in the treatment of asthma. Cromoglicic acid requires administration four times daily, and does not provide additive benefit in combination with inhaled corticosteroids.

Nezulcitinib (TD-0903) is an inhaled, lung-selective pan-Janus kinase (JAK) inhibitor used to study COVID-19-associated acute lung injury and impaired oxygenation.

Seralutinib (GB002) is an inhibitor of inhaled PDGFRα and PDGFRβ. It is used in the study for pulmonary arterial hypertension.

AZD8154 is a newly developed inhaled compound that selectively inhibits dual PI3Kγδ, aimed at treating airway inflammatory diseases.

AZD5423 is an inhaled, potent, selective, and non-steroidal modulator of the glucocorticoid receptor (GR) that effectively reduces allergen-induced responses in individuals with mild allergic asthma.

LAS195319 is a potent and selective inhaled PI3Kδ Inhibitor (IC50 = 0.5 nM) for the Treatment of Respiratory Diseases.

TPI-1020 is a novel anti-inflammatory corticosteroid and nitric oxide (NO) donor derived from budesonide. It exhibits a concentration-dependent bronchodilatory effect mediated by released NO through a cGMP-dependent pathway. Studies suggest that TPI-1020 combines corticosteroid activity with NO release, potentially benefiting the treatment of acute bronchoconstriction events in asthma and allowing for a reduced dose of inhaled beta(2)-adrenoceptor agonists.

PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 is an effective inhibitor of inhaled p38 MAPK. PF-03715455 displays some selectivity for p38α over p38β (respective IC50: 0.88 and 23 nM). PF-0371545

Abediterol (LAS100977) is a new potent, long-acting inhaled beta (2) -adrenergic receptor agonist being developed for the treatment of asthma and chronic obstructive pulmonary disease.

Batefenterol Succinate is a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties.

Methylhexanamine hydrochloride is a fatty amine and vasoconstrictor that functions as a nasal decongestant when inhaled through the nasal mucosa.

Ensifentrine (Ensifentrinum) is a PDE3 4 inhibitor, although its affinity for PDE3(IC50: 0.4 nM) is 3,440 times higher than that for PDE4(IC50: 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.

Zy 15109 can be used as inhaled mast cell stabilizer.

Aztreonam lysine is an inhaled anti-pseudomonal treatment for people who have pulmonary Pseudomonas aeruginosa infection with cystic fibrosis (CF).